Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · IEX Real-Time Price · USD
12.29
+0.12 (0.99%)
At close: Jul 19, 2024, 4:00 PM
12.30
+0.01 (0.08%)
Pre-market: Jul 22, 2024, 7:08 AM EDT
Sage Therapeutics Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Sage Therapeutics stock have an average target of 18, with a low estimate of 8.00 and a high estimate of 25. The average target predicts an increase of 46.46% from the current stock price of 12.29.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for SAGE stock from 19 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 2 | 3 | 2 | 2 | 2 | 2 |
| Hold | 13 | 13 | 13 | 14 | 14 | 14 |
| Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Total | 15 | 16 | 17 | 19 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Hold Maintains $18 → $16 | Hold | Maintains | $18 → $16 | +30.19% | Jul 19, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $23 → $18 | Buy | Maintains | $23 → $18 | +46.46% | Jul 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $25 | Hold | Reiterates | $25 | +103.42% | Jul 2, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 28, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $28 → $23 | Buy | Maintains | $28 → $23 | +87.14% | Jun 20, 2024 |
Financial Forecast
Revenue This Year
43.15M
from 86.46M
Decreased by -50.09%
Revenue Next Year
133.59M
from 43.15M
Increased by 209.57%
EPS This Year
-6.70
from -9.05
EPS Next Year
-5.25
from -6.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 59.6M | 613.8M | 1.1B | 1.8B | 2.7B |
| Avg | 43.2M | 133.6M | 293.8M | 404.8M | 618.3M |
| Low | 31.1M | 51.3M | 89.5M | 89.0M | 118.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -31.0% | 1,322.3% | 723.4% | 521.8% | 560.8% |
| Avg | -50.1% | 209.6% | 120.0% | 37.8% | 52.8% |
| Low | -64.0% | 19.0% | -33.0% | -69.7% | -70.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -5.20 | 3.77 | 12.68 | 20.48 | 24.87 |
| Avg | -6.70 | -5.25 | -3.19 | -0.30 | 1.67 |
| Low | -7.15 | -7.38 | -7.10 | -5.39 | -4.09 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.